Buy Abivax After Obefazimod Clears the Hurdle - Upside Is Real, Risk Is Manageable

Hook & thesis

Abivax just proved obefazimod can do the hard thing - deliver robust Phase 3 efficacy in ulcerative colitis with remission rates north of 50% - and then backed that clinical story with serious capital: an oversubscribed $800M ADS offering priced at $125 per share. Those two facts together change the math. The market's June panic around reported cancer cases in maintenance data is a headline risk, not (in my read) a terminal clinical failure. With efficacy intact and cash raised, the company can push commercialization planning and label-defining safety follow-up without the immediate cash overhang that often drags biotechs down.

I am initiating a buy on ABVX for the long-term (180 trading days) trade. Entry: $137.60. Stop loss: $115.00. Target: $220.00. This is a high-conviction, high-risk biotech trade: the upside is driven by obefazimod's commercial potential and the short-term risk is safety perception and regulatory scrutiny.

What Abivax does and why the market should care

Abivax SA develops biopharmaceutical products including commercial vaccines and a pipeline centered around obefazimod, an oral, non-immunosuppressant therapy for inflammatory bowel disease (ulcerative colitis and potentially Crohn's). Therapies that can induce durable remission without generalized immunosuppression are highly valued because they change long-term safety/tolerability dynamics and broaden the candidate pool of patients. The Phase 3 remission data (reported in early June) put obefazimod on the map as a potential category leader for a large market.

Concrete numbers that matter

• Current price: $137.605 (market cap ~ $12.01B).
• Shares outstanding: ~ 87.30M; float ~ 74.66M.
• 52-week range: $9.25 - $148.83 (the company has been through a dramatic move over the past year).
• Technicals are constructive: 9-day EMA ~ $135.06, 21-day EMA ~ $126.50, RSI ~ 62, MACD showing bullish momentum.
• Short interest has come down in June - days to cover near 1.45 (06/30 settlement), indicating less crowded shorting than earlier in the spring.
• Capitalization event: On 07/01/2026 Abivax priced and upsized a U.S. ADS offering to $800M at $125 per ADS; trading on Euronext resumed the same day.

Valuation framing

At ~ $12.0B market cap today, Abivax is priced like a company with a near-term major commercial opportunity. That valuation reflects both the market's enthusiasm for obefazimod's Phase 3 efficacy and the recent run-up in the shares (+1,000% over the prior year at one point). It also reflects the fact that Abivax already markets some vaccines, giving a non-zero commercial footprint to the company narrative.

Valuation has compressed relative to the peak - the 52-week high was $148.83 - however, the market will ultimately price Abivax on the probability-weighted commercial success of obefazimod and timing to approval. The recent $800M offering provides a runway that materially reduces near-term financing risk; that alone should allow the stock to trade more on clinical and commercial milestones rather than headline financing anxiety.

Catalysts to watch (2-5)

• Regulatory dialogue and submission planning - any clarity on timelines for a potential EMA or FDA filing will be a major re-rating event.
• Post-hoc and subgroup safety analyses addressing the cancer cases in the maintenance arm - published, independent adjudication or external committee commentary could materially reduce headline risk.
• Commercial preparations or partnerships - distribution, pricing and launch plans in major markets will signal management's conviction and de-risk commercialization execution.
• Real-world data or additional trial readouts (e.g., Crohn's or longer maintenance follow-up) that confirm durable remission and safety.

Trade plan - actionable

My trade is directional on the stock and the program, structured for a long-term run-up tied to regulatory and commercial de-risking. Key parameters:

• Entry: $137.60 (current market price).
• Stop loss: $115.00. This level is below recent short-term moving averages and serves as a hard technical cut if momentum reverses or if fresh safety/regulatory negatives emerge.
• Target: $220.00. This target assumes a path where obefazimod's safety profile is satisfactorily contextualized, regulatory filing timelines are reasonable, and the market begins to price in peak sales that justify a materially higher multiple vs today. At $220, implied market cap is roughly $19.2B (using ~87.3M shares), which would be consistent with peer valuations for first-in-class therapies with multi-billion-dollar peak sales potential.
• Horizon: long term (180 trading days). I expect the main drivers to play out over quarters - safety adjudications, regulatory interactions and early commercial planning - not intraday or purely technical moves.

Why this makes sense now

Two simultaneous developments create a constructive environment: (1) clinical proof of concept at Phase 3 with remission >50% which materially raises the probability of approval, and (2) a large, oversubscribed $800M offering that gives Abivax the cash to advance regulatory work and early commercialization without immediate dilution pressure. Technical indicators - EMA crossovers and a bullish MACD - add short-term confirmation that market participants are willing to buy pullbacks into the $125 - $140 area.

Risks and counterarguments

• Safety signal could be material. The reported cancer cases in the maintenance cohort are the headline risk. If a causal link to obefazimod emerges or regulators demand extensive additional safety studies, timelines and labeling could be significantly impaired.
• Regulatory uncertainty. Even compelling efficacy doesn't guarantee a smooth path to approval. Regulators may require more data, longer follow-up or restrictions that reduce commercial potential.
• Valuation premium already built in. The market cap near $12.0B reflects high expectations. Any execution slip (clinical, regulatory, or commercial) could lead to sharp downside, especially given the stock's prior volatility.
• Competition and market dynamics. The IBD space is competitive; payers will scrutinize pricing and incremental benefit versus existing biologics and small molecules.
• Dilution/financing execution. The $800M offering reduces near-term cash risk, but future needs or partnering terms could dilute shareholders or delay commercialization economics.

Counterargument: The skeptical case is straightforward - the safety events are not just noise and will materially change the approval calculus. In that scenario, the stock could revisit materially lower levels. That is why the stop is strict and the trade size must reflect biotech-position risk tolerance.

What would change my mind

I will downgrade or exit if any of the following occur: (a) independent adjudication links obefazimod mechanistically to an increased cancer risk requiring a large additional study; (b) regulators signal they will not accept the current dossier and demand new pivotal trials; (c) commercial partnerships or launch preparations stall despite the cash cushion, implying persistent execution problems. Conversely, a positive regulatory interaction with a clear filing path or an encouraging safety adjudication would strengthen the bullish thesis and likely accelerate position sizing.

Conclusion

Abivax is a high-risk, high-reward biotech story where the biggest question - does obefazimod work? - now has a positive answer on efficacy. The financing removes a major execution overhang and allows the company to focus on safety adjudication and regulatory strategy. For traders and investors with an appetite for binary biotech moves, buying ABVX here with a disciplined stop at $115 and a long-term target of $220 is a reasonable way to participate in the upside while keeping downside defined. Position sizing should reflect the elevated clinical and regulatory risk.

Trade idea: Buy ABVX at $137.60, stop $115.00, target $220.00. Horizon: long term (180 trading days).